Spots Global Cancer Trial Database for renal cell carcinoma
Every month we try and update this database with for renal cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| 3D-biomodels for Surgical Planning in Patients With Renal Cancer and Vascular Involvement | NCT03738488 | Renal Cell Carc... Three-Dimension... Venous Thrombos... | 3D printing + i... Images | 14 Years - | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | |
| Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | NCT04198766 | Solid Tumor Non-Small Cell ... Melanoma Head and Neck C... Gastric Cancer Renal Cell Carc... Urothelial Carc... | INBRX-106 - Hex... Pembrolizumab 2... Pembrolizumab 4... | 18 Years - | Inhibrx, Inc. | |
| Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) | NCT02338570 | Renal Cell Carc... | Everolimus | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma | NCT00782275 | Renal Cell Carc... Kidney Cancer | bevacizumab temsirolimus | 18 Years - | Dana-Farber Cancer Institute | |
| Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2. | NCT01339962 | Renal Cell Carc... | Non-interventio... | 18 Years - | Pfizer | |
| Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy | NCT00310115 | Bladder Cancer Cervical Cancer Esophageal Canc... Gastric Cancer Head and Neck C... Kidney Cancer Leukemia Liver Cancer Lung Cancer Pancreatic Canc... Tobacco Use Dis... | Smoking Prevent... Counseling Inte... Counseling Inte... | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase I Evaluating Integration of HypofractionatedStudy Renal Ablative Radiotherapy | NCT02264548 | Renal Cell Carc... | Radio-Ablation | 18 Years - | Lawson Health Research Institute | |
| A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors | NCT01176500 | Colon Cancer Lung Cancer Cervical Cancer Renal Cell Carc... Uterine Cancer | (18)Fluciclatid... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Using Virtual Reality (VR) Models for Preoperative Planning | NCT03334344 | Kidney Cancer Renal Cell Carc... | Ceevra Reveal | 18 Years - | Ceevra, Inc. | |
| Use of Tracking Devices to Locate Abnormalities During Invasive Procedures | NCT00102544 | Adenocarcinoma Prostate Neopla... Prostate Cancer Renal Cell Carc... Von Hippel Lind... | EM Tracking | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent | NCT00836745 | Renal Cell Carc... | Non Interventio... | 18 Years - 75 Years | Pfizer | |
| Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma | NCT02689167 | Kidney Neoplasm... Metastatic Rena... | Sunitinib | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
| A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | NCT05229601 | Soft Tissue Sar... Renal Cell Carc... Uterine Carcino... Hepatocellular ... Head and Neck S... Melanoma | HFB301001 | 18 Years - | HiFiBiO Therapeutics | |
| A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) | NCT05030506 | Renal Cell Carc... | Belzutifan Pembrolizumab Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC) | NCT03063762 | Renal Cell Carc... | Atezolizumab Bevacizumab RO6874281 | 18 Years - | Hoffmann-La Roche | |
| Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | NCT02568267 | Breast Cancer Cholangiocarcin... Colorectal Canc... Head and Neck N... Lymphoma, Large... Melanoma Neuroendocrine ... Non-Small Cell ... Ovarian Cancer Pancreatic Canc... Papillary Thyro... Primary Brain T... Renal Cell Carc... Sarcomas Salivary Gland ... Adult Solid Tum... | Entrectinib | 18 Years - | Hoffmann-La Roche | |
| CRLX101 Plus Bevacizumab in Advanced RCC | NCT01625936 | Renal Cell Carc... | CRLX101 (Cerule... Bevacizumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | NCT02867592 | Adrenal Cortica... Alveolar Soft P... Central Nervous... Childhood Clear... Clear Cell Sarc... Ewing Sarcoma Hepatoblastoma Hepatocellular ... Osteosarcoma Recurrent Adren... Recurrent Alveo... Recurrent Clear... Recurrent Ewing... Recurrent Hepat... Recurrent Hepat... Recurrent Kidne... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Recurrent Renal... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Refractory Adre... Refractory Alve... Refractory Clea... Refractory Ewin... Refractory Hepa... Refractory Hepa... Refractory Mali... Refractory Oste... Refractory Prim... Refractory Prim... Refractory Rena... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory Wilm... Renal Cell Carc... Rhabdomyosarcom... Soft Tissue Sar... Solid Neoplasm Thyroid Gland M... Wilms Tumor | Cabozantinib Cabozantinib S-... Pharmacological... | 2 Years - 30 Years | National Cancer Institute (NCI) | |
| Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer | NCT02219711 | Advanced Cancer | MGCD516 | 18 Years - | Mirati Therapeutics Inc. | |
| A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION | NCT04262375 | Non Small Cell ... Renal Cell Carc... | Durvalumab Oleclumab | 18 Years - | University Health Network, Toronto | |
| Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial | NCT02160600 | Renal Cell Carc... Renal Cysts Transitional Ce... AML | Standard multip... split bolus Dua... | 18 Years - | All India Institute of Medical Sciences, New Delhi | |
| Patient Reported Outcome After Nephron Sparing Treatment of Small Renal Tumours | NCT04040530 | Renal Cell Carc... Quality of Life | CT-guided cryoa... Partial nephrec... | 18 Years - | Region of Southern Denmark | |
| Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study) | NCT02809404 | Breast Cancer Renal Cell Carc... | Everolimus | 18 Years - | Radboud University Medical Center | |
| TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | NCT03829436 | Hepatocellular ... Metastatic Cast... Renal Cell Carc... Non-small Cell ... Colorectal Canc... Squamous Cell C... Triple-Negative... Urothelial Carc... Cholangiocarcin... GastroEsophagea... Pancreatic Canc... Sarcoma | Part 1 TPST-112... Part 2 TPST-112... Part 3 TPST-112... Part 4 TPST-112... | 18 Years - | Tempest Therapeutics | |
| Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | NCT03190174 | Ewing Sarcoma PEComa Epithelioid Sar... Desmoid Tumor Chordoma Non Small Cell ... Urothelial Carc... Melanoma Renal Cell Carc... Squamous Cell C... Hepatocellular ... Classical Hodgk... Colorectal Canc... MTOR Activating... | Nab-Rapamycin Nivolumab | 12 Years - | Sarcoma Oncology Research Center, LLC | |
| A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors | NCT05180799 | Solid Tumor, Ad... NSCLC Urothelial Carc... Gastric Cancer Small Cell Lung... Hepatocellular ... Cervical Carcin... Melanoma Renal Cell Carc... Carcinoma | BA3071 Nivolumab Pembrolizumab | 18 Years - | BioAtla, Inc. | |
| Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) | NCT00100685 | Renal Cell Carc... Metastases | Volociximab (an... | 18 Years - | Abbott | |
| Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | NCT05769959 | Renal Cell Carc... Non-small Cell ... Pancreatic Aden... Colorectal Canc... Ovarian Neoplas... | RO7515629 tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II) | NCT01613846 | Renal Cell Carc... | Sorafenib+Pazop... Pazopanib+Soraf... | 18 Years - 85 Years | Technical University of Munich | |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | NCT03517488 | Melanoma Breast Carcinom... Hepatocellular ... Urothelial Carc... Squamous Cell C... Renal Cell Carc... Colorectal Carc... Non-small Cell ... Gastric or Gast... Endometrial Car... Mesothelioma Neuroendocrine ... Cervical Cancer Small Cell Lung... Squamous Cell C... Castration-Resi... Nasopharyngeal ... Cholangiocarcin... Basal Cell Carc... Ovarian Carcino... Fallopian Tube ... Thymoma Thymic Carcinom... Squamous Cell C... Vulvar Carcinom... Solid Tumors Wi... Malignant Adnex... Non-squamous Ce... | XmAb20717 | 18 Years - | Xencor, Inc. | |
| SUTENT® In The First Line Treatment Of Renal Cell Carcinoma | NCT00460798 | Renal Cell Carc... | Sutent: observa... | - | Pfizer | |
| A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer | NCT00448721 | Renal Cell Carc... | Perifosine | 18 Years - | AEterna Zentaris | |
| Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) | NCT00100685 | Renal Cell Carc... Metastases | Volociximab (an... | 18 Years - | Abbott | |
| Patient Reported Outcome After Nephron Sparing Treatment of Small Renal Tumours | NCT04040530 | Renal Cell Carc... Quality of Life | CT-guided cryoa... Partial nephrec... | 18 Years - | Region of Southern Denmark | |
| Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma | NCT04974671 | Renal Cell Carc... Metastatic Rena... Oligoprogressiv... Progression | Stereotactic Bo... | 18 Years - | Yale University | |
| Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC | NCT02143492 | Kidney Cancer Renal Cell Carc... Advanced Renal ... | 18 Years - | Argos Therapeutics | ||
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | NCT04485013 | Cancer | TTX-080 TTX-080 pembrolizumab cetuximab | 18 Years - | Tizona Therapeutics, Inc | |
| Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma | NCT01482520 | Hepatocellular ... Renal Cell Carc... | - | Samsung Medical Center | ||
| Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma | NCT00557830 | Renal Cell Carc... | Sorafenib Escal... Sorafenib Stand... | 18 Years - | Accelerated Community Oncology Research Network | |
| Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma | NCT00176280 | Renal Cell Carc... | Leukine Dexamethasone | 18 Years - | University of Kentucky | |
| Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland | NCT00980213 | Neoplasms Renal Cell Carc... | sunitinib | 18 Years - 85 Years | Tampere University Hospital | |
| Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer | NCT00923845 | Renal Cell Carc... Graft-Versus-Ho... Engraftment Syn... | Pentostatin Sirolimus Cyclophosphamid... Allogeneic Hema... Th2 rapa cells Donor Lymphocyt... Induction Thera... GVHD prophylaxi... Donor Hematopoi... | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Follow-up After Metastasectomy in Patients With Kidney Cancer | NCT00918775 | Renal Cell Carc... | Follow-Up Care Laboratory Biom... | - | M.D. Anderson Cancer Center | |
| Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma | NCT00556049 | Renal Cell Carc... Neoplasm Metast... | Gemcitabine Sunitinib | 18 Years - | Massachusetts General Hospital | |
| CD8 Minibody Repeatability Study | NCT05744128 | Melanoma Renal Cell Carc... | Zirconium 89Zr ... | 18 Years - | ImaginAb, Inc. | |
| Circulating Tumor Cell Reducing No-touch Nephrectomy | NCT05070637 | Renal Cell Carc... Circulating Tum... | No-touch laparo... Conventional la... Laparoscopic to... | 18 Years - | Hospital de Santa Maria, Portugal | |
| Advantage of a Fast-recovery Protocol for Minimally Invasive Kidney Surgery | NCT04601129 | Renal Cell Carc... | enhanced recove... | 18 Years - 75 Years | University Hospital, Lille | |
| GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma | NCT00244764 | Carcinoma, Rena... | GW786034 Placebo | 21 Years - | GlaxoSmithKline | |
| Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes | NCT05534854 | Renal Tumor His... Kidney Cancer Renal Cell Carc... Familial Renal ... HLRCC VHL Syndrome BAP1 Tumor Pred... FLCN Gene Mutat... ALK Gene Mutati... FH Gene Mutatio... Birt-Hogg-Dube ... MET Gene Mutati... Cutaneous Leiom... Cutaneous Leiom... | Gene test | 2 Years - | RenJi Hospital | |
| Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma | NCT00044564 | Carcinoma, Rena... | Bay 59-8862 | 18 Years - | Bayer | |
| Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma | NCT04049344 | Metastatic Rena... | Decitabine; Oxa... | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Biomarkers of Response to Systemic Treatments in FH-deficient RCC | NCT05243173 | Metabolomics Renal Cell Carc... FH-Deficient RC... Systemic Treatm... | Sequencing | 18 Years - | RenJi Hospital | |
| Metabolomic Profiling in Renal Cell Carcinoma | NCT02001493 | Renal Cell Carc... | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | ||
| APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | NCT03502330 | Advanced Melano... Non-small Cell ... Renal Cell Carc... | APX005M Cabiralizumab Nivolumab | 18 Years - | Yale University | |
| Renal Cell Carcinoma Microenvironment Discovery Project | NCT04005183 | Renal Cell Carc... | 18 Years - | University Health Network, Toronto | ||
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | NCT02496208 | Bladder Small C... Bladder Squamou... Bladder Urothel... Clear Cell Rena... Invasive Bladde... Invasive Bladde... Invasive Sarcom... Kidney Medullar... Malignant Genit... Malignant Solid... Penile Carcinom... Penile Squamous... Renal Cell Carc... Renal Pelvis Ur... Sarcomatoid Ren... Stage III Bladd... Stage III Penil... Stage III Renal... Stage III Renal... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Penile... Stage IV Renal ... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Ureter Urotheli... Urethral Urothe... | Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking | NCT00790569 | Bladder Cancer Cervical Cancer Esophageal Canc... Gastric Cancer Head and Neck C... Kidney Cancer Leukemia Liver Cancer Lung Cancer Pancreatic Canc... Tobacco Use Dis... | nicotine varenicline placebo | 18 Years - 120 Years | Butler Hospital | |
| An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo | NCT02763761 | Renal Cell Carc... Melanoma Lung Cancer | Infliximab + Pr... Methylprednisol... | 18 Years - | Bristol-Myers Squibb | |
| BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC) | NCT01453595 | Renal Cancer | BEZ235 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders | NCT00001238 | Kidney Cancer Urologic Malign... Renal Cell Carc... Familial Renal ... Clear Cell Rena... | 2 Years - | National Institutes of Health Clinical Center (CC) | ||
| An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION) | NCT04941768 | Carcinoma, Rena... | 18 Years - | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | ||
| Comparison of Microwave Ablation-Assisted Enucleation and Conventional Laparoscopic Partial Nephrectomy in the Treatment of T1a Renal Cell Carcinoma | NCT02326558 | Renal Cell Carc... | laparoscopic mi... conventional la... | 15 Years - 80 Years | RenJi Hospital | |
| Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors | NCT02390843 | Retinoblastoma Clear Cell Sarc... Renal Cell Carc... Rhabdoid Tumor Wilms Tumor Hepatoblastoma Neuroblastoma Germ Cell Tumor... Ewings Sarcoma Non-rhabdomyosa... Osteosarcoma Rhabdomyosarcom... | Simvastatin Cyclophosphamid... Topotecan Myeloid growth ... | 1 Year - 29 Years | Emory University | |
| Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors | NCT00625456 | Melanoma Lung Cancer Renal Cell Carc... Squamous Cell C... | Recombinant Vac... | 18 Years - | SillaJen, Inc. | |
| Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) | NCT02338570 | Renal Cell Carc... | Everolimus | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer | NCT05420519 | Metastatic Tumo... Renal Cell Carc... Advanced Cancer | CD70 CAR-T cell... | 18 Years - | Chongqing Precision Biotech Co., Ltd | |
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | NCT03212404 | Lung Neoplasms Carcinoma, Non-... Carcinoma, Smal... Malignant Mesot... Head and Neck C... Melanoma Merkel Cell Car... Renal Cell Carc... Urothelial Carc... Classical Hodgk... Cutaneous Squam... Non Hodgkin Lym... Endometrial Can... | CK-301 (cosibel... | 18 Years - | Checkpoint Therapeutics, Inc. | |
| Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma | NCT01028638 | Metastatic Rena... | 89Zr-bevacizuma... | 18 Years - | University Medical Center Groningen | |
| Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) | NCT03177239 | Renal Cell Carc... Papillary Renal... Papillary Renal... Chromophobe Ren... Sarcomatoid Ren... Xp11 Translocat... | Nivolumab Ipilimumab | 18 Years - | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | |
| A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy | NCT06255223 | Renal Cell Carc... Radiotherapy Immune Checkpoi... | High-dose Radio... Low-dose Radiot... Anti-PD-1 monoc... | 18 Years - 80 Years | Jinling Hospital, China | |
| Treatment Resistance Following Anti-cancer Therapies | NCT04436120 | Disease Progres... | De novo tumor t... Research blood ... | 18 Years - | Pfizer | |
| BMS 247550 to Treat Kidney Cancer | NCT00030992 | Renal Cell Carc... | BMS-247550 Ranitidine Diphenhydramine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Pre-Surgical Sutent in Renal Cell Carcinoma (RCC) | NCT00715442 | Renal Cell Carc... | Sunitinib Nephrectomy | - | M.D. Anderson Cancer Center | |
| An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037 | NCT00884520 | Lung Cancer Squamous Cell C... Head and Neck C... Hepatic Carcino... Renal Cell Carc... | [F-18] VM4-037 | 18 Years - | Siemens Molecular Imaging | |
| Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan | NCT02776644 | Renal Cell Carc... | - | Pfizer | ||
| Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | NCT04106167 | Advanced Solid ... Lymphoma Gastric Cancer Colorectal Canc... Head and Neck C... Squamous Cell C... EGFR Positive S... HER2-positive B... Hepatocellular ... Small-cell Lung... Renal Cell Carc... Pancreas Cancer Melanoma NSCLC Urothelial Carc... Cervical Cancer Microsatellite ... Merkel Cell Car... | Allogeneic natu... | 18 Years - | Fate Therapeutics | |
| Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma | NCT04831138 | Renal Cell Carc... | MRI with ASL | 18 Years - | University of Texas Southwestern Medical Center | |
| A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | NCT03343613 | Solid Tumor Non Small Cell ... Renal Cell Carc... Triple Negative... | LY3381916 LY3300054 | 18 Years - | Eli Lilly and Company | |
| Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours | NCT02855203 | Renal Cell Carc... | Stereotactic Ab... Pembrolizumab | 18 Years - | Peter MacCallum Cancer Centre, Australia |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
